Systemic Therapy of Atopic Dermatitis: Welcome to the Revolution

被引：0
作者：
Eichenfield, Lawrence F. [1 ,2 ,3 ,4 ]
Gold, Linda F. Stein [5 ]
机构：
[1] Univ Calif San Diego, Sch Med, Dermatol & Pediat, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Sch Med, Dept Dermatol, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Sch Med, Pediat & Adolescent Dermatol, La Jolla, CA 92093 USA
[4] Univ Calif, Rady Childrens Hosp, San Diego, CA USA
[5] Henry Ford Hlth Syst, Dermatol Res, Detroit, MI USA
来源：
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY | 2017年 / 36卷
关键词：
Atopic dermatitis; dupilumab; fezakinumab; JAK inhibitors; lebrikizumab; nemolizumab; systemic therapy; tralokinumab; PLACEBO; MANAGEMENT; DUPILUMAB; TRIAL;
D O I：
10.12788/j.sder.2017.051
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Until recently, systemic therapy of atopic dermatitis was limited to off-label use of immunomodulators, which can pose significant safety concerns, and treatment with systemic corticosteroids, not recommended in the most recent guidelines. The introduction of dupilumab in 2017 marked a major advance in systemic therapy for atopic dermatitis. It has demonstrated long-term efficacy in adults with moderate to severe disease, and is being studied in children. Several other biologic agents and "small molecules" with varying mechanisms of action are in phase 2 or 3 development. (C) 2017 published by Frontline Medical Communications
引用
收藏
页码：S103 / S105
页数：3
相关论文
共 10 条
  • [1] [Anonymous], 2017, DUP PACK INS
  • [2] Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
    Blauvelt, Andrew
    de Bruin-Weller, Marjolein
    Gooderham, Melinda
    Cather, Jennifer C.
    Weisman, Jamie
    Pariser, David
    Simpson, Eric L.
    Papp, Kim A.
    Hong, H. Chih-Ho
    Rubel, Diana
    Foley, Peter
    Prens, Errol
    Griffiths, Christopher E. M.
    Etoh, Takafumi
    Pinto, Pedro Herranz
    Pujol, Ramon M.
    Szepietowski, Jacek C.
    Ettler, Karel
    Kemeny, Lajos
    Zhu, Xiaoping
    Akinlade, Bolanle
    Hultsch, Thomas
    Mastey, Vera
    Gadkari, Abhijit
    Eckert, Laurent
    Amin, Nikhil
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Stahl, Neil
    Yancopoulos, George D.
    Shumel, Brad
    [J]. LANCET, 2017, 389 (10086) : 2287 - 2303
  • [3] Cork MJ, 2017, AM AC DERM M ORL FL
  • [4] Eichenfield LF, 2017, ANN M AM AC DERM ORL
  • [5] A pathogenic role for Th22/IL-22 in atopic dermatitis is established by a placebo-controlled trial with an anti IL-22/ILV-094 mAb
    Guttman-Yassky, E.
    Khattri, S.
    Brunner, P. M.
    Neumann, A.
    Malik, K.
    Fuentes-Duculan, J.
    Garcet, S.
    Suarez-Farinas, M.
    Lebwohl, M.
    Krueger, J. G.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S53 - S53
  • [6] Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis
    Ruzicka, Thomas
    Hanifin, Jon M.
    Furue, Masutaka
    Pulka, Grazyna
    Mlynarczyk, Izabela
    Wollenberg, Andreas
    Galus, Ryszard
    Etoh, Takafumi
    Mihara, Ryosuke
    Yoshida, Hiroki
    Stewart, Jonathan
    Kabashima, Kenji
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (09) : 826 - 835
  • [7] Guidelines of care for the management of atopic dermatitis
    Sidbury, Robert
    Davis, Dawn M.
    Cohen, David E.
    Cordoro, Kelly M.
    Berger, Timothy G.
    Bergman, James N.
    Chamlin, Sarah L.
    Cooper, Kevin D.
    Feldman, Steven R.
    Hanifin, Jon M.
    Krol, Alfons
    Margolis, David J.
    Paller, Amy S.
    Schwarzenberger, Kathryn
    Silverman, Robert A.
    Simpson, Eric L.
    Tom, Wynnis L.
    Williams, Hywel C.
    Elmets, Craig A.
    Block, Julie
    Harrod, Christopher G.
    Begolka, Wendy Smith
    Eichenfield, Lawrence F.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 71 (02) : 327 - 349
  • [8] Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
    Simpson, E. L.
    Bieber, T.
    Guttman-Yassky, E.
    Beck, L. A.
    Blauvelt, A.
    Cork, M. J.
    Silverberg, J. I.
    Deleuran, M.
    Kataoka, Y.
    Lacour, J. -P.
    Kingo, K.
    Worm, M.
    Poulin, Y.
    Wollenberg, A.
    Soo, Y.
    Graham, N. M. H.
    Pirozzi, G.
    Akinlade, B.
    Staudinger, H.
    Mastey, V.
    Eckert, L.
    Gadkari, A.
    Stahl, N.
    Yancopoulos, G. D.
    Ardeleanu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (24) : 2335 - 2348
  • [9] When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council
    Simpson, Eric L.
    Bruin-Weller, Marjolein
    Flohr, Carsten
    Ardern-Jones, Michael R.
    Barbarot, Sebastien
    Deleuran, Mette
    Bieber, Thomas
    Vestergaard, Christian
    Brown, Sara J.
    Cork, Michael J.
    Drucker, Aaron M.
    Eichenfield, Lawrence F.
    Foelster-Holst, Regina
    Guttman-Yassky, Emma
    Nosbaum, Audrey
    Reynolds, Nick J.
    Silverberg, Jonathan I.
    Schmitt, Jochen
    Seyger, Marieke M. B.
    Spuls, Phyllis I.
    Stalder, Jean-Francois
    Su, John C.
    Takaoka, Roberto
    Traidl-Hoffmann, Claudia
    Thyssen, Jacob P.
    van der Schaft, Jorien
    Wollenberg, Andreas
    Irvine, Alan D.
    Paller, Amy S.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (04) : 623 - 633
  • [10] Wollenberg A, 2017, AM AC DERM M ORL FL
1